TrialCompass TCL
Back to results
Early Phase 1Not yet recruitingPriority 4 · Lower priorityNCT05728879

Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

ClinicalTrials.gov

Plain-language summary

This Early Phase 1 trial is studying APR-TD011 (RLF-TD011) for people with cutaneous T-cell lymphoma (skin lymphoma). The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years or older
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

APR-TD011 (RLF-TD011) (COMBINATION_PRODUCT): APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.

Drugs / treatments
APR-TD011 (RLF-TD011)
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

NCT05728879

Phase: Early Phase 1 | Status: Not yet recruiting | Priority: Lower

Plain-language summary

This Early Phase 1 trial is studying APR-TD011 (RLF-TD011) for people with cutaneous T-cell lymphoma (skin lymphoma). The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 1 US location.

Who can join

  • Age 18 Years or older
  • See full trial listing for complete eligibility

What's being tested

APR-TD011 (RLF-TD011) (COMBINATION_PRODUCT): APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.

Drugs / treatments: APR-TD011 (RLF-TD011)

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 30 patients

Primary endpoint: Change in microbiome species

Ages: 18 Years to —

Start date: 2027-01 | Est. completion: 2028-12

Locations

1 US sites · 1 total

Illinois

Contact

Dermatology CTU | NUderm-research@northwestern.edu | 312-503-5944

Sponsor: Northwestern University (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05728879

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.